Recent Updates
Recently added Catalysts
PHGE Positive Sentiment

BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024

Key Takeaway: BiomX Inc. announced a conference call scheduled for November 14, 2024, to discuss its third quarter financial results and provide updates on business operations and programs. The company is focused on developing phage therapies targeting specific pathogenic bacteria, addressing chronic diseases with unmet needs. Investors can participate via a call or through a webcast available on the company's website.
Price reaction · baseline $14.0334 (2024-11-11 close) · hit after-hours · 1 other PHGE headline(s) in the window, move may be shared
day 0 close · peak
+4.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • BiomX is advancing innovative natural and engineered phage therapies.
  • The company is addressing specific pathogenic bacteria with significant unmet medical needs.
  • They are utilizing a proprietary platform (BOLT) to customize treatments.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+190%
120-day peak, hindsight
Typical move
13.4%
average across 4 past catalysts
Cash runway
~1 mo
High dilution risk
Lead asset
BX002-A
Phase 1 · Healthy Volunteers

Full Press Release Details

NESS ZIONA, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Thursday, November 14, 2024, at 8:00 a.m. ET, to report third quarter 2024 financial results and provide business and program updates.
To participate in the conference call, please dial 1-877-407-0724 (U.S) or 1-201-389-0898 (International). The live and archived webcast will be available in the Investors section of the Company’s website at www.biomx.com.
BiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT (“BacteriOphage Lead to Treatment”) platform to customize phage compositions against these targets. For more information, please visit www.biomx.com, the content of which does not form a part of this press release.

Frequently Asked Questions

When is BiomX's next conference call?

The next conference call is on November 14, 2024, at 8:00 a.m. ET.

How can I participate in the conference call?

To join, call 1-877-407-0724 (U.S) or 1-201-389-0898 (International).

What is BiomX focused on developing?

BiomX is developing natural and engineered phage therapies to target pathogenic bacteria.

Where can I find the webcast of BiomX's conference call?

The webcast will be available on the Investors section of BiomX's website.

What does BiomX's BOLT platform do?

The BOLT platform customizes phage compositions to target specific bacterial pathogens.

Last updated: Nov 12, 2024